日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer

临床前研究和平行 II 期试验评估反义 STAT3 寡核苷酸和检查点阻断对晚期胰腺癌、非小细胞肺癌和错配修复缺陷型结直肠癌的疗效

Chad Tang #, Genevieve P Hartley #, Coline Couillault, Ying Yuan, Heather Lin, Courtney Nicholas, Anupallavi Srinivasamani, James Dai, Ecaterina E Ileana Dumbrava, Siqing Fu, Daniel D Karp, Aung Naing, Sarina A Piha-Paul, Jordi Rodon Ahnert, Shubham Pant, Vivek Subbiah, Timonthy A Yap, Apostolia M T

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

RLY-4008,首个对FGFR2改变和耐药突变均具有活性的高选择性FGFR2抑制剂

Vivek Subbiah #,Vaibhav Sahai #,Dejan Maglic,Kamil Bruderek,B Barry Touré #,Songping Zhao,Roberto Valverde,Patrick J O'Hearn,Demetri T Moustakas,Heike Schönherr,Nastaran Gerami-Moayed,Alexander M Taylor,Brandi M Hudson #,Damian J Houde,Debjani Pal,Lindsey Foster,Hakan Gunaydin,Pelin Ayaz,Dina A Sharon #,Lipika Goyal #,Alison M Schram,Suneel Kamath,Cori Ann Sherwin,Oleg Schmidt-Kittler,Kai Yu Jen,Fabien Ricard,Beni B Wolf,David E Shaw,Donald A Bergstrom,James Watters,Jessica B Casaletto

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

INBRX-109(一种第三代重组人源化死亡受体5激动剂抗体)在软骨肉瘤中的临床前表征和I期试验结果

Vivek Subbiah ,Sant P Chawla ,Anthony P Conley ,Breelyn A Wilky ,Anthony Tolcher ,Nehal J Lakhani ,David Berz ,Vasily Andrianov ,William Crago ,Monica Holcomb ,Abrahim Hussain ,Carson Veldstra ,James Kalabus ,Brianne O'Neill ,Lane Senne ,Emily Rowell ,Analeah B Heidt ,Katelyn M Willis ,Brendan P Eckelman

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

Tilsotolimod 利用 TLR9 通路促进实体肿瘤中的抗原呈递和 1 型 IFN 信号传导:一项多中心国际 I/II 期试验 (ILLUMINATE-101)

Hani Babiker, Erkut Borazanci, Vivek Subbiah, Sanjiv Agarwala, Alain Algazi, Jacob Schachter, Michael Lotem, Corinne Maurice-Dror, Daniel Hendler, Shah Rahimian, Hans Minderman, Cara Haymaker, Daruka Mahadevan, Chantale Bernatchez, Ravi Murthy, Rolf Hultsch, Nadia Kaplan, Gregory Woodhead, Charles H

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib

L730V/I RET 屋顶突变对 pralsetinib 和 selpercatinib 表现出不同的活性

Tao Shen #, Xueqing Hu #, Xuan Liu #, Vivek Subbiah, Blaine H M Mooers, Jie Wu

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition

mTOR 突变作为对 AKT 抑制的获得性耐药机制出现,以及随后对 mTORC1/2 抑制的反应

Niamh Coleman, Vivek Subbiah, Shubham Pant, Keyur Patel, Sinchita Roy-Chowdhuri, Sireesha Yedururi, Amber Johnson, Timothy A Yap, Jordi Rodon, Kenna Shaw, Funda Meric-Bernstam

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

RET 溶剂前沿突变介导 RET 驱动的恶性肿瘤对选择性 RET 抑制产生获得性耐药性

Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist, Geoffrey R Oxnard, Oliver Gautschi, Alexander Drilon, Vivek Subbiah, Christine Khoo, Edward Y Zhu, Michele Nguyen, Dahlia Henry, Kevin R Con

Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials

在转移性实体瘤临床试验中,无进展生存期并非总生存期的最佳预测指标。

Pasalic, Dario; McGinnis, Gwendolyn J; Fuller, C David; Grossberg, Aaron J; Verma, Vivek; Mainwaring, Walker; Miller, Austin B; Lin, Timothy A; Jethanandani, Amit; Espinoza, Andres F; Diefenhardt, Markus; Das, Prajnan; Subbiah, Vivek; Subbiah, Ishwaria M; Jagsi, Reshma; Garden, Adam S; Fokas, Emmanouil; Rödel, Claus; Thomas, Charles R Jr; Minsky, Bruce D; Ludmir, Ethan B

Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials

三期随机癌症临床试验的试验赞助和报告时间

Lin, Timothy A; Fuller, Clifton David; Verma, Vivek; Mainwaring, Walker; Espinoza, Andres F; Miller, Austin B; Jethanandani, Amit; Pasalic, Dario; Das, Prajnan; Minsky, Bruce D; Thomas, Charles R Jr; Fogelman, David R; Subbiah, Vivek; Subbiah, Ishwaria M; Ludmir, Ethan B

IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers

尤文氏肉瘤的 IGF-1R/mTOR 靶向治疗:与蛋白质组学和放射学预测生物标志物相匹配的五项 IGF-1R 相关试验的荟萃分析

Hesham M Amin, Ajaykumar C Morani, Najat C Daw, Salah-Eddine Lamhamedi-Cherradi, Vivek Subbiah, Brian A Menegaz, Deeksha Vishwamitra, Ghazaleh Eskandari, Bhawana George, Robert S Benjamin, Shreyaskumar Patel, Juhee Song, Alexander J Lazar, Wei-Lien Wang, Razelle Kurzrock, Alberto Pappo, Peter M Ande